Casirivimab/imdevimab (Ronapreve®). HTA ID: 21067

Assessment Status Rapid Review complete
HTA ID 21067
Drug Casirivimab/imdevimab
Brand Ronapreve®
Indication For the treatment and prevention of COVID-19.
Assessment Process
Rapid review commissioned 20/12/2021
Rapid review completed 01/02/2022
Rapid review outcome On the basis of current evidence, the NCPE recommends that casirivimab/imdevimab not be considered for reimbursement at this time*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.